Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

It has been about a month since the last earnings report for Veracyte (VCYT). Shares have lost about 13.6% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Veracyte due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out, estimates review flatlined during the past month.The consensus estimate has shifted -9.76% due to these changes.VGM ScoresCurrently, Veracyte has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookVeracyte has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerVeracyte belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Integra LifeSciences (IART), has gained 3.1% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.Integra reported revenues of $382.65 million in the last reported quarter, representing a year-over-year change of +3.7%. EPS of $0.41 for the same period compares with $0.55 a year ago.For the current quarter, Integra is expected to post earnings of $0.43 per share, indicating a change of -31.8% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.Integra has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veracyte, Inc. (VCYT): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks